Trading a CLYM straddle lets you take a pure volatility position on Climb Bio Inc without committing to a direction. Climb Bio Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate CLYM straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on CLYM profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Climb Bio Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the CLYM straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the CLYM straddle is the cleanest expression of that view. Our scanner prices every CLYM straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a CLYM straddle into a catalyst or short a CLYM straddle to harvest decay, the options straddle setups that matter are all in one place.
